Professor Andrew Tutt qualified in Medicine in 1990. After completing postgraduate training in General Medicine, he trained in Clinical Oncology at the Royal Marsden Hospital, before gaining a Predoctoral Research Training Fellowship from the Medical Research Council to work in Professor Alan Ashworth’s laboratory, at The Institute of Cancer Research in 1997.

There he worked on the then-unknown DNA repair functions of the BRCA2 breast cancer predisposition gene and described the role of BRCA2 in homologous recombination (HR). He was awarded his PhD in 2002. In his postdoctoral work as a Clinician Scientist, he identified the
synthetic lethality between PARP inhibitors and BRCA1/2 mutations with Dr. Chris Lord and Professor Alan Ashworth.

He went on to design the single agent PARP inhibitor Proof of Concept Phase I trials and associated DNA repair biomarker studies with the ICR and Royal Marsden Drug Development Unit and has since led international Phase II and III trials, examining the role of HR-directed
therapies, including PARP inhibitors and platinums for BRCA1 / BRCA2 deficiency-associated malignancy including; the OlympiA and TNT trials, which have changed clinical practice guidelines for patients with BRCA1 and BRCA2 mutated breast cancer.

He cares for women with breast cancer as a Consultant Oncologist and as a member of the multidisciplinary Breast Units at Guy’s and St Thomas’ and Royal Marsden NHS Foundation Trusts. Andrew is a member of the St Gallen Early Breast Cancer International Consensus Panel, the Oxford Early Breast Cancer Trialists Cooperative Group (EBCTCG), and is Chair of the CRUK Experimental Medicine Expert Review Panel.

He is a member of the ESMO Breast Cancer Guidelines Group and serves on the ESMO annual Scientific Committee meeting. He is a Professor of Breast Oncology, Head of the Division of Breast Cancer Research, and Director of the Breast Cancer Now Toby Robins Research Centre, at the Institute of Cancer Research in London (ICR), and a Professor of Clinical Oncology at King’s College London (KCL) where he is also the Director of the Breast Cancer Now Research Unit.

Andrew leads a clinical trial program focusing on TNBC and cancers associated with functional deficiencies in DNA repair including BRCA1, BRCA2, and PALB2. He leads a translational laboratory across the ICR and KCL, studying therapy targets, biomarkers, and resistance mechanisms in these cancers.

His ICR laboratory is run as a joint endeavor with biologist colleague, Professor Christopher Lord. In 2015 he received the Addarii Award from the University of Bologna for his work in the field of BRCA1 and BRCA2-associated breast and ovarian cancer research.

In 2019 Andrew was elected to the Fellowship of the Academy of Medical Sciences and was awarded the ESMO Breast Cancer Award in 2021. In 2022 he was awarded the AACR Team Science Award with the ICR/RMH Breast Cancer Research Team. He was also elected a European Fellow of the Academy of Cancer Sciences in 2022.